27
Participants
Start Date
March 31, 2007
Primary Completion Date
November 30, 2008
Study Completion Date
November 30, 2008
Dornase alfa
2.5 mg inhalation dose twice daily for 14±2 days
placebo
2.5 mg inhalation dose twice daily for 14±2 days
Long Island Jew Adult CF Ctr, New Hyde Park
Albany Medical College, Albany
SUNY Upstate Medical Univ, Syracuse
University of Pittsburgh, Pittsburgh
W Virginia Univ Health Sci Ctr, Morgantown
Duke Pediatric Clinical, Durham
Pediatric Pulmonary Assoc, Columbia
Medical Univ of South Carolina, Charleston
Brown Univ School of Medicine, Atlanta
Medical College of Georgia, Augusta
Pulm & Critical Care Assoc, Jacksonville
Central Florida Pulmonary Grou, Orlando
Univ of Miami, Miami
University of Alabama, Birmingham
Univ of Kentucky Med Ctr, Lexington
Toledo Childrens Hospital, Toledo
Rainbow Babies & Child Hosp, Cleveland
Wayne State University, Detroit
Michigan State University, Kalamazoo
Spectrum Hospital, Grand Rapids
Univ of Minnesota Dept of Derm, Minneapolis
Rush Medical Center, Chicago
Pulmonary & Critical Care Med, St Louis
Santiago Reyes MD-Private Prac, Oklahoma City
CF Solutions, Inc, Tulsa
Baylor College of Medicine, Houston
Alamo Clinical Research Assoc, San Antonio
Nat'l Jewish Med/Research Ctr, Denver
Children's Lung Specialist, Las Vegas
Childrens Hospital of LA, Los Angeles
USC Adult CF Center, Los Angeles
CHOC, Orange
Ventura County Medical Ctr, Ventura
Capital Allergy Resp Dis Ctr, Sacramento
Univ of Michigan Hlth System, Ann Arbor
University of Mississippi, Jackson
Monmouth Medical Center, Long Branch
Morristown Memorial Hospital, Morristown
St. Peters Univ Hospital, New Brunswick
University of New Mexico, Albuquerque
Lead Sponsor
Genentech, Inc.
INDUSTRY